MedTrace Logo

Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation

NCT03483324 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2022-05-31

No results posted yet for this study

Summary

A phase 1b, open label, multi-center trial of AB-110 in adults with hematologic malignancies, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplasia (MDS) undergoing cord blood transplantation. Subjects will receive unmanipulated cord blood (UCB) and AB-110 expanded CD34 enriched hematopoietic progenitor cells (HSPC).

Conditions

Interventions

BIOLOGICAL

Unmanipulated Umbilical Cord Blood (UCB)

Human leukocyte antigen (HLA) matched umbilical cord blood

BIOLOGICAL

AB-110

Expanded cord blood stem cells and engineered human endothelial cells

Sponsors & Collaborators

  • California Institute for Regenerative Medicine (CIRM)

    collaborator OTHER

  • Angiocrine Bioscience

    lead INDUSTRY

Principal Investigators

  • Paul Finnegan, MD · Angiocrine Bioscience

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-24
Primary Completion
2020-12-21
Completion
2022-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03483324 on ClinicalTrials.gov